Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 395 Neoplasms 350 Carcinoma, Non-Small-Cell Lung 313 Prostatic Neoplasms 264 Colorectal Neoplasms 236 Lung Neoplasms 204 Multiple Myeloma 163 Pancreatic Neoplasms 147 Ovarian Neoplasms 146 Neoplasm Metastasis 141 Leukemia, Myeloid, Acute 138 Melanoma 118 Squamous Cell Carcinoma of Head and Neck 100 Carcinoma, Renal Cell 93 Stomach Neoplasms 92 Recurrence 92 Lymphoma 91 Lymphoma, Non-Hodgkin 89 Endometrial Neoplasms 89 Carcinoma, Hepatocellular 89 Precursor Cell Lymphoblastic Leukemia-Lymphoma 87 Glioblastoma 85 Brain Neoplasms 84 Head and Neck Neoplasms 77 Glioma 76 Uterine Cervical Neoplasms 75 Urinary Bladder Neoplasms 72 Sarcoma 70 Leukemia, Lymphocytic, Chronic, B-Cell 70 Hematologic Neoplasms 68

Interventions

pembrolizumab 1 Paclitaxel 1 Carboplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Squamous Non-small Cell Lung Cancer × 30 days × Clear all

NCT07221474 2026-05-28

INTerpath-13

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡